euralgic amyotrophy: Central reorganization and rehabilitation after peripheral dysfunctio

Completed

Conditions: Neuralgic amyotrophy
ParsonageTurner syndrome
Brachial Neuritis
10034606

Registration Number: NL-OMON44371

Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 75

Inclusion Criteria

General:
1. Aged * 18 years
2. Right-handed
3. Able to provide informed consent;Neuralgic amyotrophy (NA) patients:
1. Diagnosis of NA
2. NA predominantly present in the right upper extremity
3. In subacute or chronic phase of NA (i.e. no inflammation of plexus, >2-3 months after attack onset)
4. Presence of scapular dyskinesia

Exclusion Criteria

General:
1. Pregnancy
2. Severe comorbidity
3. A history of or recent surgery, biomechanical constraints and/or periarticular fractures of the arm/shoulder
4. Any other neuromusculair disease affecting the shoulder girdle
5. Any central nervous system disorder, neurological disorder (e.g. Parkinson, cerebrovasculair accident, etc.)
For undergoing MRI experiment:
6. Presence of an active implant and/or any non-removable metal parts in or on the upper body
7. Claustrophobia
8. Epilepsy ;NA patients
1. (Prior) NA attacks of the left upper extremity or lumbosacral plexus
2. Patients in the acute phase of NA (characterized by severe pain and inflammation of the brachial plexus)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>For the cross-sectional comparison, as well as for the neuroimaging part of the<br /><br>randomized controlled trial, the main parameters are changes/differences in the<br /><br>magnitudes of mean functional MRI signal (BOLD activity) related to motor<br /><br>imagery of the affected arm, quantifying changes in central motor control.<br /><br><br /><br>For the clinical part of the randomized controlled trial, the main parameter is<br /><br>change in functional (dis)ability of the shoulder, arm and hand, measured with<br /><br>the Shoulder Rating Questionnaire (SRQ), after a 17-week treatment period. </p><br>

Secondary Outcome Measures